XKH 001
Alternative Names: Anti-IL-25 monoclonal antibody - Kanova Biopharmaceutical; XKH-001Latest Information Update: 28 Jul 2025
At a glance
- Originator Kanova Biopharmaceutical
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Asthma
- No development reported Hypersensitivity; Inflammation
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for phase-I development in Allergy(In volunteers) in China (SC, Injection)
- 28 Jul 2025 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in China (SC, Injection)
- 08 Jul 2025 Zhejiang Kanova Biopharmaceutical plans to initiate a phase II trial for Atopic Dermatitis in China (SC) (NCT07054736)